| Literature DB >> 28496465 |
Najmeh Mahjoubi1, Ahmad Fazeli2, Rassoul Dinarvand3, Mohammad Reza Khoshayand1, Maryam Shekarchi4, Mohammad Reza Fazeli5.
Abstract
Liquid protein formulations are prone to form aggregates. The effect of nonionic surfactants such as Polysorbate 20 (PS 20) and n-Dodecyl β-D-maltoside (DDM) on the prevention of aggregation and conformational changes of recombinant human IFNβ-1b (rhIFN β_1b) was explored. Polysorbate has been used in formulations of protein pharmaceuticals. There have been concerns about using PS 20 due to its residual peroxide content which may negatively affect protein efficacy. n-Dodecyl β-D-maltoside has been of interest and shown to be highly effective in prevention of aggregation. Fresh bulk of rhIFN β_1b was formulated using DDM or different concentrations of PS 20. Formulations were exposed to light stress condition according to the ICH guideline of Q1b. The overall conformational integrity of individual samples was characterized by a combination of Circular dichroism (CD), Fluorescence spectroscopy and RP_HPLC techniques. The CD spectrum depicting the conformational integrity of rhIFN β_1b showed 31.9% and 31.2% decreases in α-helix content of protein samples with 0.2% or 0.02% of PS20 compared to only18.2% of that containing 0.2% DDM. The RP-HPLC analysis also showed that the oxidized impurity in formulation containing DDM is less than those contain PS 20. Complementary analysis of the liquid formulations using IFR and UV methods also was in compliance with the data obtained by CD. Compared to PS 20, the sample of rhIFN β_1b formulation with DDM was more resistant to the destruction effect of light. Results were in accordance with previous studies and could suggest DDM as a reliable anti-aggregation surfactant in biopharmaceutical formulations.Entities:
Keywords: Circular dichroism (CD); Nonionic surfactant; anti-aggregation; oxidation; rhIFN β_1b
Year: 2017 PMID: 28496465 PMCID: PMC5423237
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Turbidity for dark control and light-exposed formulations as a function of nonionic surfactant concentration (DDM or PS20).Turbidity was assessed by absorbance at 350nm (OD350). Formulations contained either 0.2% PS20 or 0.02% PS20 or 0.2% DDM.
Figure 2OD 280nm/OD 260nm for dark control and light-exposed formulations as a function of nonionic surfactant concentration (DDM or PS20). Formulations contained either 0.2% PS20 or 0.02% PS20 or 0.2% DDM.
Figure 3Fluorescence emission spectra of dark control and light-exposed formulations containing nonionic surfactant (DDM or PS20). Formulations contained either 0.2% PS20 or 0.02% PS20 or 0.2% DDM.
Figure 4Far-UV CD spectra for dark control and light-exposed formulations containing nonionic surfactant (DDM or PS20). Formulations contained either 0.2% PS20 or 0.02% PS20 or 0.2% DDM.
Figure 5Oxidized rhIFN β_1b detected by RP-HPLC analysis. Formulations containing either 0.2% PS 20 or 0.02% PS20 or 0.2% DDM, respectively.